Free UK shipping
Results in under 14 days
UK lab
10% Off All Tests - Summer 2025
Nortriptyline is part of the tricyclic antidepressant (TCA) family, first introduced in 1963 (22). Although originally developed for depression, today it is also prescribed for several other conditions, including neuropathic (nerve-related) pain and migraine prevention.
TCAs like nortriptyline were among the earliest modern antidepressants and played a role in what was sometimes called the “psychopharmacological revolution,” when safer, more effective medicines began to replace older psychiatric treatments (22).
Nortriptyline is part of the tricyclic antidepressant (TCA) family—an older class of medications first introduced in 1959 (9). It works by increasing the levels of certain brain chemicals, including serotonin and noradrenaline, which influence both mood and how the body processes pain (9).
Although TCAs are generally as effective as newer antidepressants such as selective serotonin reuptake inhibitors (SSRIs), they are linked to more side effects and a higher likelihood of patients stopping treatment. This is why SSRIs—like fluoxetine (Prozac) and citalopram—are usually preferred as first-line treatments for depression (9, 8).
That said, nortriptyline has a somewhat different side-effect profile to its close relative amitriptyline, and is often considered to be better tolerated with fewer risks (4, 23). Because of this, nortriptyline is sometimes chosen in cases where patients have not responded well to other options.
Nortriptyline has multiple actions in the body (4, 20, 24, 8, 9):
It prevents the reuptake of noradrenaline more strongly than amitriptyline, boosting its levels in the brain.
It also affects serotonin, contributing to its antidepressant effect.
It blocks several types of receptors, including adrenergic (involved in blood pressure and alertness), muscarinic (linked to memory and digestion), and histaminic (linked to allergy and sleep).
Like other TCAs, it shows anti-inflammatory effects, which are being studied for their role in conditions such as neuropathic pain, pain sensitisation, and even atherosclerosis (16, 1).
This broad pharmacology is part of why nortriptyline has both benefits and risks. Its side effects are generally less tied to heart problems than amitriptyline, but they can still be significant, especially in older adults (20, 9).
One important effect of nortriptyline is its anticholinergic activity. This means it reduces the action of a brain chemical called acetylcholine, which plays a role in memory, attention, and coordination.
Although nortriptyline’s anticholinergic effects are weaker than those of amitriptyline, they can still lead to problems such as:
Memory loss
Confusion
Delirium (sudden confusion and disorientation)
Increased risk of falls
A higher chance of triggering or worsening dementia
The overall impact of these effects across all the medications a person takes is called the anticholinergic burden (11, 12, 13).
Anticholinergic burden is particularly important in older adults, many of whom are prescribed multiple medications. Even drugs with mild anticholinergic activity—such as those for urinary incontinence or irritable bowel syndrome—can add to the total burden.
Healthcare professionals are especially mindful of this risk in older patients because:
Multiple medicines can add together to create a stronger effect.
Stress, hospital stays, frailty, or polypharmacy (taking many medicines) can make symptoms worse.
The longer a person is exposed, the greater the impact.
Symptoms can be mistaken for “normal ageing,” delaying the real cause being recognised.
Anticholinergic effects interfere with the brain’s natural protective mechanisms, possibly accelerating inflammation and neurodegeneration.
Misdiagnosis can lead to a “prescribing cascade,” where extra drugs are added to treat side effects rather than stopping the cause.
Nortriptyline contributes less to anticholinergic burden than amitriptyline but is still considered a moderate-to-high risk drug, often classed as Category 2–3 on the Anticholinergic Burden Scale (10).
Nortriptyline is less likely than amitriptyline to cause serotonin syndrome, but the risk is not zero. Because it increases serotonin, nortriptyline can interact with:
Other antidepressants (SSRIs, MAO inhibitors)
Painkillers such as tramadol and certain opioids
Supplements such as St John’s Wort or tryptophan
Serotonin syndrome is a rapid-onset condition that can occur within 1 hour in about 30% of cases, or within 6 hours in about 60% of cases (17).
Symptoms include:
Mental changes: agitation, anxiety, confusion, seizures, coma
Muscle symptoms: tremors, poor coordination, rhythmic jerks (myoclonus)
Autonomic symptoms: sweating, diarrhoea, fever, very high temperature (>40°C), rapid heart rate (tachycardia)
Not all symptoms need to be present for diagnosis. Serotonin syndrome can be mild but is sometimes life-threatening—urgent medical attention is required.
All TCAs, including nortriptyline, can increase the risk of QT prolongation—a change in the heart’s electrical rhythm that can lead to dangerous arrhythmias. This risk is generally higher for TCAs than SSRIs, and among TCAs, amitriptyline is the most strongly associated (7).
Symptoms (15):
Palpitations
Light-headedness or fainting
Weakness
Seizures (in some cases)
Risk factors (15):
Female sex
Older age
Use of multiple QT-prolonging drugs
Electrolyte imbalances (low potassium, magnesium, or calcium)
Heart disease, heart failure, or recent heart attack
Liver or kidney dysfunction
Genetic predisposition (e.g., Long QT Syndrome)
If you experience these symptoms, seek immediate medical attention.
Nortriptyline is toxic in overdose, though generally considered slightly less so than amitriptyline (24, 17). Symptoms may include:
Dry mouth
Low blood pressure (hypotension)
Seizures
Serious heart arrhythmias
Dilated pupils
Urinary retention
Coma (mild to severe)
Tackling pain and depression
Nortriptyline is mainly prescribed for two conditions: depression and neuropathic (nerve-related) pain (18). Although first developed as an antidepressant, nortriptyline is now commonly used in pain management, particularly when pain has a nerve component.
How and when to take it
Adults: Start at a low dose, gradually increasing if needed to 75–100 mg per day. This can be taken as divided doses or as a single daily dose.
Maximum dose: 150 mg per day.
Older adults: Start low, with careful increases if necessary. Typical range: 30–50 mg per day, in divided doses.
Adults: Start with 10 mg once daily, usually at night.
Dose may be increased gradually up to 75 mg daily.
Higher doses should only be given under specialist supervision.
Nortriptyline’s side effects reflect its pharmacology, but compared to amitriptyline, they are generally milder in terms of sedation and anticholinergic load (20, 4, 8).
Drowsiness or fatigue
Constipation
Dry mouth
Dizziness
Headache
Palpitations
Nortriptyline can block alpha-adrenergic receptors, which influence blood pressure and alertness. This can cause:
Low blood pressure when standing (orthostatic hypotension)
Dizziness
Sedation
Nortriptyline has about half the anticholinergic activity of amitriptyline. Anticholinergic means reducing the action of acetylcholine, a brain chemical important for memory, attention, and coordination. This can lead to:
Blurred vision
Dry mouth
Difficulty passing urine (urinary retention)
Fast heart rate (tachycardia)
Acute angle-closure glaucoma (a serious eye condition)
Confusion
Delirium
Nortriptyline is much less potent than amitriptyline at blocking histamine receptors—about 25 times less. Even so, this action may still cause:
Sedation
Increased appetite
Weight gain
Confusion
Delirium
Suicidal thoughts or ideation (especially in younger patients)
Increased risk of seizures
Abnormal liver function tests
Your genes play an important role in how your body processes nortriptyline. Variants in certain enzymes can affect whether the medicine reaches a therapeutic level or causes unwanted side effects (18, 20).
After oral dosing, peak blood concentrations of nortriptyline occur after about 7–8.5 hours. However, this does not mean patients will feel the therapeutic effect immediately—clinical benefit may take several weeks to appear.
Nortriptyline’s metabolism is simpler than amitriptyline’s. Unlike many other TCAs, nortriptyline does not form additional active metabolites because it is a secondary amine.
Nortriptyline is mainly broken down by the CYP2D6 enzyme into inactive products.
Ultrarapid metabolisers (people with highly active CYP2D6 genes) may break down nortriptyline too quickly, preventing the drug from reaching effective levels. In this case, an alternative medication not metabolised by CYP2D6 may be recommended.
Poor metabolisers (those with reduced CYP2D6 activity) process nortriptyline too slowly. This increases the risk of side effects such as low blood pressure when standing (postural hypotension) and cardiac problems. For these patients, treatment should usually begin at 50% of the standard starting dose, with close clinical monitoring.
Nortriptyline is eliminated mainly through the urine. Roughly one-third of the dose is excreted within 24 hours.
Nortriptyline is mainly broken down by an enzyme called CYP2D6. Your genes affect how active this enzyme is, which can change how well the medicine works and whether side effects appear (19, 8, 20).
Slow metabolisers (poor CYP2D6 function): The drug stays in the body longer, increasing the risk of side effects. Doctors may recommend starting at a lower dose.
Fast metabolisers (ultrarapid CYP2D6 function): The drug is cleared too quickly, so it may not reach effective levels. In these cases, an alternative medicine may be a better choice.
Most people (normal metabolisers): Standard doses usually work as expected.
Drug interactions can also mimic genetic effects—for example, some antidepressants block CYP2D6 and raise nortriptyline levels.
Pharmacogenetic factors may also be important for other TCAs:
Protriptyline
Desipramine
(CYP2D6 is key across the class; CYP2C19 matters more for the tertiary-amine TCAs listed above.)
Explore PGx for Mental Health(1) https://www.mdpi.com/1424-8247/18/2/197 (2) https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2017.00307/full (3) https://www.mdpi.com/2227-9059/5/2/24 (4) https://pmc.ncbi.nlm.nih.gov/articles/PMC2014120/ (5) https://www.nature.com/articles/s41392-024-01738-y (6) https://systematicreviewsjournal.biomedcentral.com/articles/10.1186/s13643-020-01296-8 (7) https://pmc.ncbi.nlm.nih.gov/articles/PMC5972123/ (8) https://www.ncbi.nlm.nih.gov/books/NBK537225/ (9) https://www.ncbi.nlm.nih.gov/books/NBK557791/ (10) https://pmc.ncbi.nlm.nih.gov/articles/PMC9427617/ (11) https://journals.sagepub.com/doi/10.1177/20451253231195264 (12) https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2019.01309/full (13) https://onlinelibrary.wiley.com/doi/10.1111/jnc.15244 (14) https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bcp.15261 (15) https://pmc.ncbi.nlm.nih.gov/articles/PMC4110870/ (16) https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2023.1072629/full (17) https://pmc.ncbi.nlm.nih.gov/articles/PMC6539562/ (18) https://www.nice.org.uk/about/what-we-do/evidence-and-best-practice-resources/british-national-formulary--bn (19) https://pmc.ncbi.nlm.nih.gov/articles/PMC5478479/ (20) https://www.ncbi.nlm.nih.gov/books/NBK482214/ (21) https://pmc.ncbi.nlm.nih.gov/articles/PMC6493872/ (22) https://pmc.ncbi.nlm.nih.gov/articles/PMC9048453/?utm_source=chatgpt.com (23) https://pubmed.ncbi.nlm.nih.gov/7395525/ (24) https://pmc.ncbi.nlm.nih.gov/articles/PMC11141239/ (25) https://pubmed.ncbi.nlm.nih.gov/9537821/ (26) https://www.ncbi.nlm.nih.gov/books/NBK541006/ (27) https://www.ncbi.nlm.nih.gov/books/NBK557656/ (28) https://www.researchgate.net/publication/372475601_Therapeutic_drug_monitoring_of_imipramine_correlation_with_a_case_study (29) https://www.ncbi.nlm.nih.gov/books/NBK542306/ (30) https://pmc.ncbi.nlm.nih.gov/articles/PMC4027305/ (31) https://pubmed.ncbi.nlm.nih.gov/39202/ (32) https://www.sciencedirect.com/science/article/abs/pii/002839089190160D (33) https://link.springer.com/article/10.1007/BF02190274 (34) https://pubmed.ncbi.nlm.nih.gov/2693055/ (35) https://pmc.ncbi.nlm.nih.gov/articles/PMC3555062/